AAN and AHS Release Updated Migraine Prevention Guideline for Adults

The American Academy of Neurology (AAN) and the American Headache Society (AHS) have released a joint practice guideline update aimed at helping clinicians choose the most effective medications for preventing migraines in adults. The new recommendations, published in the journals *Neurology* and *Headache*, build on the 2012 guideline and incorporate the latest evidence from clinical trials and systematic reviews.

The update provides a detailed, evidence‑based ranking of preventive therapies, including beta‑blockers, antiepileptics, and newer monoclonal antibodies targeting calcitonin gene‑related peptide pathways. It also outlines patient‑specific considerations such as comorbid conditions, drug interactions, and tolerability profiles. The American Academy of Family Physicians has endorsed the guidelines, underscoring their relevance for primary care providers who often initiate migraine prevention.

By offering a clearer framework for medication selection, the revised guidelines aim to improve treatment outcomes and reduce the burden of migraine on patients and healthcare systems. Clinicians are encouraged to review the full recommendations to integrate them into routine practice.